DuoCort Pharma’s Orphan Drug Plenadren® Granted European Marketing Authorization for Adrenal Insufficiency.
- Details
- Published on Monday, 07 November 2011 00:00
Helsingborg, Sweden and Exton, PA, US November 7th, 2011– The Swedish specialty pharma company, DuoCort Pharma, announced today that the European Commission has granted a European Marketing Authorisation for Plenadren® (hydrocortisone, modified release tablet), an orphan drug for treatment of adrenal insufficiency in adults, bringing these patients their first pharmaceutical innovation in over 50 years.
DuoCort inks deal to sell Plenadren®
- Details
- Published on Thursday, 27 October 2011 00:00
Helsingborg, Sweden – DuoCort AB announces it has signed a definitive agreement to sell DuoCort Pharma AB and its orphan drug Plenadren® to the biopharmaceutical company ViroPharma Incorporated. Plenadren® is a new treatment for adrenal insufficiency, also called Addison´s disease. The total potential deal value exceeds one billion SEK of which 220 million SEK will be paid by ViroPharma on closing.
Positive Opinion from CHMP for Plenadren®
- Details
- Published on Friday, 22 July 2011 00:00
Helsingborg July 22nd 2011– The Swedish specialty pharma company,
DuoCort Pharma announced today that the Committee for Medicinal Products
for Human Use (CHMP) of the European Medicines Agency issued a positive
opinion recommending marketing authorisation of its product Plenadren, a
novel treatment for adrenal insufficiency.
DuoCort Pharma and Clinigen sign agreement on named patient programme for Plenadren
- Details
- Published on Thursday, 28 April 2011 00:00
Helsingborg/ Burton on Trent – The Swedish specialty pharma company, DuoCort Pharma and UK-based Clinigen, the global provider of specialist and unlicensed medicines, announce that they have concluded an agreement whereby Clinigen will manage a Named Patient Programme for Plenadren, a novel treatment for Addison´s disease. The product has orphan status in Europe and the USA and is currently in the European Union (EU) registration process for marketing authorisation.
Read more: DuoCort Pharma and Clinigen sign agreement on named patient programme for Plenadren
DuoCort Pharma and Recipharm start innovative collaboration
- Details
- Published on Wednesday, 27 October 2010 00:00
Helsingborg/Stockholm – DuoCort Pharma announces it has concluded an agreement with Recipharm under which Recipharm is set to scale-up the manufacturing of DuoCort’s tablets to commercial scale as DuoCort Pharma prepares for market entry with its orphan drug for the treatment of Addison’s disease.
Read more: DuoCort Pharma and Recipharm start innovative collaboration
Better quality of life with new orphan drug for Addison´s disease
- Details
- Published on Monday, 21 June 2010 00:00
Helsingborg / San Diego - DuoCort Pharma´s new physiological treatment for adrenal insufficiency improves patients' quality of life. The Swedish pharmaceutical company presents new data from its phase II/III trial at the 92nd annual ENDO congress in San Diego today.
Read more: Better quality of life with new orphan drug for Addison´s disease
DuoCort seeks European market authorisation for orphan drug
- Details
- Published on Wednesday, 16 June 2010 13:32
Helsingborg - The Swedish speciality pharma company DuoCort Pharma takes a step closer to the market by applying for market authorisation in EU for its new treatment for the rare and life threatening disease adrenal insufficiency, often referred to as Addison´s disease.
Read more: DuoCort seeks European market authorisation for orphan drug
Article on DuoCort in European Life Science
- Details
- Published on Saturday, 07 November 2009 09:19
European Life Science, autumn edition, features an article about DuoCort. Read it here.
Maria Forss selected in Swedish Initiative for Women Board Members
- Details
- Published on Wednesday, 01 July 2009 01:00
PULS’s Head of Business Development, Maria Forss, is one of the 200
women selected by Maud Olofsson, the Minister for Enterprise and Energy
and Deputy Prime Minister, in collaboration with ALMI Företagspartner,
to participate in the Styrelsekraft program. This is a national
mentoring program targeting qualified and experienced women who have the
ambition to be board members of both private and public companies.
Read more: Maria Forss selected in Swedish Initiative for Women Board Members
New chronotherapy for Addison´s disease
- Details
- Published on Tuesday, 30 June 2009 20:56
Helsingborg Sweden June 29th 2009 - DuoCort publishes data
from its Phase I study for the rare and life threatening disease
adrenal insufficiency. The release profile of DuoCort’s new form of
treatment with once-a-day hydrocortisone dosing closely resembles the
physiological secretion pattern. The data is published today in the European Journal of Endocrinology , a leading scientific journal for endocrinology.